ODN 2216 |
| カタログ番号GC66339 |
ODN 2216 は、TLR9 (Toll-like receptor 9) リガンドまたはアゴニストです。 ODN 2216 は大量の IFN-α を誘発します。およびIFN-β。 ODN 2216 は IFN-α を誘発します。 pDC（形質細胞様DC）およびDC（樹状細胞）によるIL-12（p40）産生による。 ODN 2216 は IFN-γ を刺激します。 IFN-α/β によって間接的に媒介される末梢血単核細胞 (PBMC) での産生。 ODN 2216 は NK 細胞を活性化し、IFN-γ を促進します。 TCR 誘発 CD4+ T 細胞の産生。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 332437-00-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ODN?2216 is a TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4+ T cells[1][2][3][4].
ODN 2216 (6 μg/mL, 9 days) drives Th1 development of naive CD4 T cells[1].
ODN?2216 (2 μM, 15 h) significantly decreased apoptosis of thymic DC[2].
Apoptosis Analysis[2]
| Cell Line: | Thymic DC, pDC |
| Concentration: | 2 μM |
| Incubation Time: | 15 h |
| Result: | Significantly decreased apoptosis of thymic DC (23.1 ± 0.9%), and naturally induced apoptosis of thymic pDC was not decreased (72.8 ± 2.9%). |
ODN 2216 induces T-cell mediated antitumor immune response in murine vaccination models[3]
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *